Jonathan Elefant

Jonathan Elefant

Jonathan Elefant
Washington, DC
+1 202 346 4023

Jonathan Elefant is an associate in Goodwin’s Business Law department and a member of its Technology & Life Sciences groups. Jonathan practices corporate law with a focus on mergers and acquisitions, finance transactions, and other general corporate matters, representing both buyers and sellers. Specifically, he has experience with structuring domestic and international mergers and acquisitions, restructurings, spin-offs, and other corporate transactions, drafting and negotiating transaction documents and managing post-closing integration.

Jonathan is known as a solutions-oriented attorney and a trusted advisor to his clients while guiding founders, executives, board members, and counsel through the lifecycles of a company. Jonathan has diverse industry experience and a track record of good business judgment, excellent management skills, and attention to detail.

Jonathan received his JD from the University of Maryland School of Law and an LLM in Taxation from the Georgetown University Law Center. Prior to joining the firm, Jonathan was an associate in the corporate department of DLA Piper LLP (US).


  • Represented Disc Medicine in connection with its reverse merger transaction with Gemini Therapeutics
  • Represented ETM Electromatic, Inc. in its sale transaction to a subsidiary of Teledyne Technologies Incorporated (NYSE:TDY)
  • Represented a publicly traded company it its US$21.4 billion worldwide acquisition of a biopharma business from the Life Sciences division of a publicly traded company
  • Represented an international company in its US$615 million cross-border public cash tender offer of a Belgian advanced biopharmaceutical company
  • Represented a healthcare technology private equity fund in its US$41 million acquisition of a leading provider of medical record retrieval and organization services and image-enabled healthcare information exchanges
  • Represented publicly traded and Fortune 500 company in cross-border transaction
  • Represented a publicly traded company it its spin-off of its dental segment into an independent, publicly-traded company
  • Represented the fourth largest US cash management company in its US$520 million sale
  • Represented one of the nation's largest swimming pool service franchises in its US$50 million sale to a parent company of home services franchisors
  • Represented a premier provider of project and risk management services to multiple federal agencies in its US$5.7 million sale to a leading technology solutions provider to the federal government
  • Represented a leading provider of integrated logistic support, training and engineering solutions to the defense, national security and first responder markets, in its US$10 million acquisition of a Florida-based company
  • Represented a leading provider of IT solutions to the federal government, in its US$59 million sale to a private equity group specializing in investments in government contractors
  • Represented an Atlanta-based private equity management firm in its US$25 million acquisition of a specialty contractor of disaster restoration services
  • Represented a publicly traded company in its US$430.8 million cash-out merger
  • Represented a leading geospatial technology company serving the US Intelligence community in its US$140 million sale to a leading provider of commercial high-resolution earth observation and advanced geospatial solutions
  • Represented a Maryland-based, venture-backed biodefense and medical device company in its US$2 million preferred equity financing
  • Represented a leading provider of on-demand marketing, promotion and print services in their internal restructuring, recapitalization and subsequent US$5.5 million acquisition of a provider of software solutions for print distributorships
  • Represented a leading gas service provider in its US$20 million acquisition of a propane business
  • Represented an artificial intelligence company specialized in the application of deep learning for target identification, drug discovery and aging research in its US$6 million Series A financing
  • Represented a healthcare compliance analytics company in its US$11 million Series B financing and US$4 million Series A financing
  • Represented a Maryland-based, venture-backed company in its US$2.5 million Series A financing
  • Represented a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines in its US$8.4 million Class C investment in an Israel-based micro-needle technology company
  • Represented a professional baseball team in a US$40 million senior secured revolving credit facility under Major League Baseball's infrastructure fund
  • Issuer’s counsel in an offering of US$399.7 million tax exempt bonds for a non-profit hospital system
  • Represented an education institution in its planning and implementation of an organizational restructuring of, and consolidation of assets among, five Maryland private school entities
  • Underwriters’ counsel in connection with at the market offering of common shares for a NYSE-listed Maryland REIT
  • Underwriters’ counsel in connection with a US$450 million issuance of notes by a multinational diversified hospitality company
  • Represented a Nasdaq company in its US$490 million initial public offering
  • Represented a Nasdaq company in its US$400 million preferred equity financing




Georgetown University Law Center


University of Maryland School of Law



  • District of Columbia
  • Maryland


  • U.S. District Court for the District of Columbia
  • U.S. District Court for the District of Maryland